Costunolide can activate the ROS/MAPK pathway in renal cell carcinoma (Fu et al., 2020), honokiol can activate the ROS/ERK1/2 pathway in OS cells (Huang et al., 2018), and metformin can activate the ROS/JNK pathway in OS cells (Li et al., 2020). Here, MAPK3 is linked to renal cell carcinoma.